Form 4: Zimmer Biomet Director Higgins Reports Stock Transactions

Arthur J. Higgins, a Director at Zimmer Biomet Holdings, Inc., reported transactions involving phantom stock units and restricted stock units.

Summary

• Arthur J. Higgins, a Director at Zimmer Biomet Holdings, Inc. (ZBH), filed a Form 4 detailing transactions related to his beneficial ownership of company securities.
• The transactions include the acquisition of phantom stock units and restricted stock units.
• These units are part of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Phantom stock units are to be settled in shares of common stock within sixty days after cessation of service as a Director.
• Restricted Stock Units are immediately vested but subject to mandatory deferral until termination of service or three years after the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity awards and holdings for a director rather than significant new investment or divestment.

Positives

• Director Arthur J. Higgins continues to hold equity in Zimmer Biomet Holdings, Inc. through phantom stock units and restricted stock units, indicating ongoing commitment.
• The restricted stock units are immediately 100% vested, providing immediate value to the reporting person.

Risks

• The value of phantom stock units and restricted stock units is tied to the performance of Zimmer Biomet Holdings, Inc. common stock, exposing the reporting person to market volatility.
• Mandatory deferral periods for restricted stock units mean the reporting person cannot access the full value until specific future events occur.

Future Outlook

The future outlook for the reported securities is dependent on the performance of Zimmer Biomet Holdings, Inc. common stock. Phantom stock units will be settled upon cessation of director service, and restricted stock units are subject to mandatory deferral until termination of service or three years post-grant.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insiders of publicly traded companies, providing transparency into their equity holdings and transactions. This filing for Zimmer Biomet Holdings, Inc. is typical for a director's compensation and equity participation within the medical device industry.

Stakeholder Impact

• Shareholders: Increased transparency into director's equity holdings and compensation structure.
• Employees: Indirect impact through the alignment of director incentives with company performance.
• Management: Reinforces standard corporate governance practices regarding executive and director compensation.

Next Steps

• Settlement of phantom stock units in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• Mandatory deferral of restricted stock units until the later of the reporting person's termination of service as a Director or three years after the grant date.

Key Dates

Keywords

Zimmer Biomet Holdings, ZBH, Form 4, Director, Beneficial Ownership, Phantom Stock Units, Restricted Stock Units, Deferred Compensation Plan, Equity